Health and Healthcare
Stem Cell Stocks Take Off (ASTM, GERN, OPXA, STEM)
Published:
Last Updated:
Tickerspy’s Stem Cell Stock Index (*RSXTM) took off today, rising nearly 13%. The movement followed a release from the National Institutes of Health (NIH) announcing that 13 embryonic stem cell lines were approved for funding.
Opexa Therapeutics Inc (NASDAQ: OPXA) led the rise in stem cell stocks, surging over 40%. The company seeks to develop treatments to major illnesses, such as multiple sclerosis and diabetes, through stem cell research. The company’s stock has risen 2837% off its lows for the year.
StemCells Inc (NASDAQ: STEM) rose over 30% to a high of $1.45. The company engages in research aimed at developing treatment for organ damage using stem cells. The company’s stock is up over 1544% off its low for the year.
Garrett W. McIntyre
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.